Search

Xenon Pharmaceuticals Inc

Open

SectorHealthcare

41.24 -1.76

Overview

Share price change

24h

Current

Min

40.54

Max

42.02

Key metrics

By Trading Economics

Income

301K

-110M

EPS

-1.11

Employees

358

EBITDA

-9.3M

-120M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+65.28% upside

Market Stats

By TradingEconomics

Market Cap

274M

3.9B

Previous open

43

Previous close

41.24

Xenon Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Nov 2026, 21:06 UTC

Xenon Pharmaceuticals Inc. closed higher, continuing its upward trend since Tuesday, with a steady rise throughout the day and strength above its 20-day moving average.

10 Nov 2026, 20:51 UTC

Social Media
News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million, and advances its drug pipeline.

9 Nov 2026, 23:02 UTC

News

Xenon Pharmaceuticals reports a Q3 net loss of $110.4 million, better than the expected $113 million loss, with operating expenses rising to $120.1 million.

6 Nov 2026, 21:03 UTC

Xenon Pharmaceuticals Inc. is trading higher, diverging from a downward shift in the broader market despite recent upward momentum in prior sessions.

5 Nov 2026, 22:11 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-market hours amid a broader market decline.

4 Nov 2026, 21:07 UTC

Xenon Pharmaceuticals Inc. gained significantly during Wednesday's trading, maintaining strong upward momentum and finishing above its 20-day moving average since Tuesday's close.

3 Nov 2026, 21:07 UTC

Xenon Pharmaceuticals Inc. is trading higher, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

2 Nov 2026, 20:52 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, positioned above its 20-day moving average and near the upper end of its one-month range.

30 Oct 2026, 20:08 UTC

Social Media
News

Stifel sets a price target of $86 for Xenon Pharmaceuticals and maintains a "Buy" rating, citing the company's developing pipeline for epilepsy treatments.

29 Oct 2026, 20:04 UTC

News
Social Media

Xenon Pharmaceuticals reports positive Phase 1 results for XEN1701 and XEN1120, supporting progression to Phase 2 studies in acute pain, presented at IASP 2026.

28 Oct 2026, 19:36 UTC

Xenon Pharmaceuticals Inc. is seeing a modest advance on Wednesday, marking three consecutive sessions of gains despite a slight pullback from its mid-morning peak.

27 Oct 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. is trading modestly higher, settling in the middle of its one-month trading range after a brief dip earlier in the day.

23 Oct 2026, 20:01 UTC

Xenon Pharmaceuticals Inc shares are declining, reversing recent gains and reflecting a downward shift since Thursday's close.

22 Oct 2026, 19:41 UTC

Xenon Pharmaceuticals Inc is experiencing higher price movement, supported by significant gains in the Biotechnology sub-sector, trading within the middle of its one-month range.

21 Oct 2026, 23:46 UTC

Xenon Pharmaceuticals Inc shares are trading lower in after-market hours, following a notable drop from an earlier high amid broader market weakness.

20 Oct 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares are advancing, having reached a peak earlier in the session, marking a significant increase within its one-month trading range.

19 Oct 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares are gaining amid a broader market trend of higher daily closes since Friday's close.

16 Oct 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares are declining sharply, continuing a downward trend since Thursday and remaining significantly below their 20-day moving average.

15 Oct 2026, 20:03 UTC

Xenon Pharmaceuticals Inc shares are advancing, influenced by a significant upward movement in the Biotechnology sub-sector, despite earlier pulling back from a session high.

14 Oct 2026, 19:21 UTC

Xenon Pharmaceuticals Inc shares fell significantly, continuing a downward trend with three consecutive sessions of losses and remaining below its 20-day moving average.

13 Oct 2026, 20:01 UTC

Xenon Pharmaceuticals Inc shares fell, breaking a trend of higher daily closes, contrasting with recent upward momentum since Monday's close.

9 Oct 2026, 20:06 UTC

Xenon Pharmaceuticals Inc shares are modestly higher, peaking in early afternoon trading.

8 Oct 2026, 19:15 UTC

Xenon Pharmaceuticals Inc shares are declining, marking five consecutive sessions lower, and remain significantly below their 20-day moving average amid ongoing market weakness.

6 Oct 2026, 20:02 UTC

Xenon Pharmaceuticals Inc shares fell sharply, continuing a downward trend with unusually high volume and remaining below the 20-day moving average.

5 Oct 2026, 20:06 UTC

News

Xenon Pharmaceuticals Inc shares are declining, continuing a trend from Friday's close, despite an earlier rebound from a session low.

2 Oct 2026, 21:01 UTC

News

Xenon Pharmaceuticals Inc announced equity inducement grants to new employees, with after-market trading showing a slight gain since Friday's close.

1 Oct 2026, 23:55 UTC

Xenon Pharmaceuticals Inc declined in after-market trading, moving lower since Thursday's close and remaining significantly below its 20-day moving average.

30 Sept 2026, 20:07 UTC

Xenon Pharmaceuticals Inc. shares fell, closing lower than Tuesday's close after an early drop, remaining below its 20-day moving average.

29 Sept 2026, 20:01 UTC

Xenon Pharmaceuticals Inc is advancing today with increased trading volume, recovering from earlier losses to reach a peak in late morning.

28 Sept 2026, 23:55 UTC

Xenon Pharmaceuticals Inc. is trading lower in after-hours, shifting from a slight gain to a more substantial loss since Monday's close, remaining below its 20-day moving average.

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

65.28% upside

12 Months Forecast

Average 69.583 USD  65.28%

High 90 USD

Low 46 USD

Based on 16 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

15

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat